Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on January 27, 2020. The filing serves to announce a Special General Meeting of shareholders scheduled for March 3, 2020, at the offices of Doron, Tikotzky, Kantor, Gutman, Nass & Amit Gross in Bnei Brak, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary event is the scheduling of a corporate governance meeting.
Guidance, Outlook, and Management Commentary
The Company is furnishing the following documents in connection with the upcoming meeting:
- Notice and Proxy Statement describing the proposal to be voted upon and voting procedures (Exhibit 99.1).
- Proxy Card for holders of ordinary shares (Exhibit 99.2).
- Voting Instruction Card for holders of American Depositary Shares (ADSs) to instruct Bank of New York Mellon (Exhibit 99.3).
The filing does not contain specific management commentary on business outlook, risks, contingencies, or unusual items beyond the procedural details of the meeting.
Key Facts for Investor Verification
- Verify the specific proposal to be voted upon in the attached Notice and Proxy Statement (Exhibit 99.1), as the summary text does not detail the subject matter.
- Confirm the record date and deadline for voting instructions, which are not specified in the cover letter but are contained in the exhibits.
- Note that the filing is signed by Eyal Leibovitz, Chief Financial Officer, on January 27, 2020.